A5007781322- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Delphi Technique in Research
- Global Cancer Incidence and Screening
- Health Systems, Economic Evaluations, Quality of Life
- Clinical practice guidelines implementation
- Cancer survivorship and care
- Statistical Methods in Clinical Trials
- Colorectal Cancer Screening and Detection
- Computational Drug Discovery Methods
- Genetic Associations and Epidemiology
- Cancer, Lipids, and Metabolism
- scientometrics and bibliometrics research
- Artificial Intelligence in Healthcare
- Research Data Management Practices
- Scientific Computing and Data Management
- Advanced Radiotherapy Techniques
- Medical Imaging Techniques and Applications
- AI in cancer detection
Baum Consult
2024
Project Management Institute
2024
Bayer (Germany)
2020-2023
University of Oxford
2023
Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, to wait until palliative treatment needed. PIONEER, funded by European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through application big data analytics. To describe clinical characteristics and long-term outcomes on conservative using international large network real-world data. From initial cohort >100 000...
Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to deprivation therapy, have been a game changer management this disease stage. However, these come with their fair share toxicities and side effects. The goal observational study is report drug-related adverse events (AEs), are correlated systemic combination for mHSPC. Determining optimal treatment option requires large...
Abstract Objective We introduce and review the concept of a study-a-thon as catalyst for open science in medicine, utilizing harmonized real world, observation health data, tools, skills, methods to conduct network studies, generating insights those wishing use study-a-thons future research. Materials Methods A series historical since 2017 present were reviewed thematic opportunity accelerate research method studies across therapeutic areas. Review publications experience authors generated...
Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients metastatic hormone-sensitive prostate cancer (mHSPC) decades. However, development docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone acetate prednisolone, apalutamide , enzalutamide darolutamide (in combination chemotherapy) has proven that treatments is more effective. Recently, intensification therapy, so-called "triplets", have emerged in...
Metastatic prostate cancer (PCa) constitutes ~5% of all new PCa diagnoses in Western countries. For most cases, primary consideration should be given to systemic therapies as the first-line approach based on evidence from randomized controlled trials (RCTs). Despite importance RCTs pinnacle modern medicine, concerns have been raised about their applicability real-life scenarios. These often feature participants who are younger with better performance statuses and prognoses compared...
Delayed palliative management (DPM) is an alternative for prostate cancer (PCa) patients with poor performance status, or those who received radical treatment but progressed and no longer meet the criteria curative treatment. PIONEER a large network of federated data analytic platforms in PCa that aims to improve its care through application big analytics. The objective this study was describe clinical baseline characteristics outcomes receiving DPM using data. Descriptive on from four...
Abstract This is a study protocol for an observational health data analysis, submitted as preprint to facilitate transparency and open science. Watchful waiting (WW) represents deferred treatment option prostate cancer (PCa) patients when curative seems overtreatment right from the outset. Patients are ‘watched’ development of local or systemic progression with disease-related symptoms, at which stage they then treated palliatively according their in order maintain quality life. When...
Watchful waiting (WW) represents a deferred treatment option for prostate cancer (PCa) patients when curative seems overtreatment right from the outset. Patients are ‘watched’ development of local or systemic progression with disease-related symptoms, at which stage they then treated palliatively according to their in order maintain quality life (QoL). When choosing WW, it is important adequately assess expectancy patients. Although previous studies reported outcomes PCa managed results...